Trials / Unknown
UnknownNCT02906280
RCT Comparing 19Ga vs 22Ga EBUS-TBNA Needles in Carcinoma.
Randomized Controlled Trial Comparing the Performance of 19 Gauge Versus 22 Gauge EBUS-TBNA Needles in Lung Carcinoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- KU Leuven · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
EBUS-TBNA is often the sole diagnostic test applied in patients with stage IV lung cancer. A limitation of the TBNA needle when using a 22 Gauge needle is the limited ability to procure adequate histological samples. Although a larger 19 Ga needle can procure histological samples as demonstrated by the conventional 19 Ga needle, published data are not existing with respect to molecular diagnostics. A new nitinol-based 19 Ga needle has been developed for EBUS-TBNA. Given the frequent usage of 22 Ga needles for molecular diagnostics and the recent technical advancements in 19 Ga needle technology, we conduct a RCT to compare the performance of both needle types.
Detailed description
All patients with (suspected) stage IV lung carcinoma identified on spiral computed tomography scan and requiring an EBUS-TBNA investigation to obtain intrathoracic hilar or mediastinal lymph node tissue for diagnosis, subtyping and genotyping of lung cancer are eligible for participation in this study. Procedural technique : patients undergo an EBUS-TBNA procedure with either the Flex 19 Ga needle or the 22 Ga needle ; all procedures are performed using a linear array echoendosope under moderate sedation (standard practice). Primary endpoint of the study is the presence of core tissue that is defined as a continuous string of material as observed on the microscopic examination. Secondary endpoints are elements relevant to molecular analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | EBUS-TBNA needle | tissue sampling |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-07-01
- Completion
- 2017-12-01
- First posted
- 2016-09-20
- Last updated
- 2016-09-20
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02906280. Inclusion in this directory is not an endorsement.